Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Circulating tumor DNA (ctDNA) has a host of benefits in treating and managing patients with early-stage disease, especially in monitoring patients both in the neoadjuvant setting and during treatment, noted Alexey Aleshin, MD, senior medical director of Oncology at biotech giant Natera.
Transcript
Why is ctDNA so important as an indicator in breast cancer?
So, breast cancer is a unique disease in that monitoring for response is critical for making management decisions. The ability to assess pathological CR [complete response] after completion of neoadjuvant therapy has really, really changed our approach to treating and managing patients with early-stage disease. However, the big limitation is, path CR can only be assessed after completing therapy. There's really a big need in the field for better biomarkers that can be dynamically monitored not only just in the neoadjuvant space, but also post surgically, as well as during surveillance.
In what ways does ctDNA proactively inform treatment in oncology?
The ctDNA space is multifaceted and rapidly evolving. So we really like to think about ctDNA as kind of really being a continuum of use cases. I think one really exciting and evolving use case is early cancer detection. So that's identifying cancer before histological diagnosis is made using circulating tumor DNA. On the other side of the continuum is the use case that I think many oncologists are familiar with, and that's using ctDNA to identify actionable or targetable mutations, so-called comprehensive or complete genomic profiling, typically reserved for patients in the advanced or metastatic setting.
I think really, the focus of today is really the middle of the spectrum. And that's really where Natera has focused on with their Signatera assay. And this is the minimal residual disease or molecular residual disease space, which really means identification of extremely low levels of ctDNA in the perioperative setting, both for assessment of residual disease after surgery, but also for treatment response monitoring in, for example, the neoadjuvant setting.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More